Cargando…
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study
We aimed to identify prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with sorafenib. We investigated 177 patients, including 116 who received sorafenib as first-line therapy, using the Cox regress...
Autores principales: | Kim, Sung Han, Kim, Sohee, Nam, Byung-Ho, Lee, Sang Eun, Kim, Choung-Soo, Seo, Ill Young, Kim, Tae Nam, Hong, Sung-Hoo, Kwon, Tae Gyun, Seo, Seong Il, Joo, Kwan Joong, Song, Kanghyon, Kwak, Cheol, Chung, Jinsoo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320076/ https://www.ncbi.nlm.nih.gov/pubmed/28271073 http://dx.doi.org/10.1155/2017/9215930 |
Ejemplares similares
-
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study
por: Kim, Sung Han, et al.
Publicado: (2015) -
Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study
por: Kang, Ho Won, et al.
Publicado: (2016) -
Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
por: Kim, Jung Kwon, et al.
Publicado: (2019) -
Survival and clinical prognostic factors in metastatic non‐clear cell renal cell carcinoma treated with targeted therapy: A multi‐institutional, retrospective study using the Korean metastatic renal cell carcinoma registry
por: Kim, Jung Kwon, et al.
Publicado: (2019) -
A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma
por: Kim, Sung Han, et al.
Publicado: (2016)